IP Library Granted Patent US 7,135,484
Granted Patent B2
US 7,135,484 · App. 10/638,381 · Granted Nov 14, 2006

Azabicyclic compounds are central nervous system active agents

Assignee: Abbott Laboratories
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,135,484
App. No.
10/638,381
Granted
Nov 14, 2006
Kind
B2
Abstract

Compounds of formula (I) are novel CNS active agents that are useful for treating pain and for treating other disorders associated with the cholinergic system.

Claims (53)

1. A compound of formula (IV)

wherein

represents a double bond;

Y is a covalent bond;

Z is CH 2 ;

R 1 is hydrogen:

R 2 is hydrogen;

R 3 and R 5 are absent; and

R 4 is heterocycle, wherein the heterocycle is selected from the group consisting of furyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrrolyl, tetrazinyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazinyl, triazolyl, benzimidazolyl, benzothiazolyl, benzothienyl, benzoxazolyl, benzofuranyl, cinnolinyl, furo[2,3-c]pyridine, furo[3,2-c]pyridine, furo[3,2-b]pyridinyl, furo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, indolyl, indolizinyl, naphthyridinyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, phthalazinyl, quinolinyl, quinolizinyl, quinoxalinyl, quinazolinyl, thieno[2,3-c]pyridine, thieno[3,2-c]pyridine, thieno[3,2-b]pyridinyl, and thieno[2,3-b]pyridinyl wherein the heterocycle is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, phenyl, triphenylmethyl (trityl), —C(NH)NR 10 R 11 , —NR 10 R 11 , (NR 10 R 11 )alkyl, (NR 10 R 11 )carbonyl, (NR 10 R 11 )carbonylalkyl, (NR 10 R 11 )sulfonyl, —NR 12 S(O) 2 R 13 , —C(NR 12 )NR 13 R 14 , —CH 2 C(NR 12 )NR 13 R 14 , —C(NOR 12 )R 13 , —C(NCN)R 12 , —C(NNR 12 R 13 )R 14 , —S(O) 2 OR 12 , and —S(O) 2 R 12 ,

wherein R 10 and R 11 are independently selected from hydrogen, alkyl or alkylcarbonyl, and R 12 , R 13 , and R 14 are independently selected from hydrogen, alkyl, aryl, or arylalkyl.

2. The compound according to claim 1 wherein the heterocycle is selected from the group consisting of imidazolyl, isoxazolyl, pyridazinyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, imidazo[1,2-a]pyridinyl, thieno[3,2-b]pyridinyl, and thieno[2,3-b]pyridinyl wherein the heterocycle is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkenyl, alkenyloxy, alkoxy, alkyl, alkynyl, cyano, halogen, nitro, phenyl, (NR 10 R 11 )sulfonyl, and —C(NH)NR 10 R 11 .

3. The compound according to claim 2 selected from the group consisting of

(cis)-5-(3-methyl-5-isoxazolyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-2-methyl-5-(3-methyl-5-isoxazolyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(3-bromo-1,2,4-thiadiazol-5-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(1,3-thiazol-2-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(3,5-dimethyl-4-isoxazolyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(1H-imidazol-4-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(1,3-thiazol-5-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(imidazo[1,2-a]pyridin-3-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(imidazo[1,2-a]pyridin-6-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(thieno[3,2-b]pyridin-2-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(1-trityl-1H-imidazol-4-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(5-(aminosulfonyl)-2-thienyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(5-(amino(imino)methyl)-2-thienyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(2-methyl-2H-tetrazol-5-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(thieno[2,3-b]pyridin-5-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(imidazo[1,2-a]pyridin-7-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(5-nitro-1,3-thiazol-2-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(1,3,4-thiadiazol-2-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(6-phenylpyridazin-3-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole; and

(cis)-2-methyl-5-(6-phenylpyridazin-3-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole.

4. The compound according to claim 1 wherein the heterocycle is pyridinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkenyl, alkenyloxy, alkoxy, alkyl, alkynyl, cyano, halogen, and nitro.

5. The compound according to claim 4 selected from the group consisting of

(cis)-5-(6-chloro-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(5-methoxy-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(6-chloro-5-methyl-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(5,6-dichloro-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(5-chloro-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(6-methyl-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(2-methyl-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(6-chloro-5-fluoro-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(6-chloro-3-pyridinyl)-2-cyanomethyl-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(6-fluoro-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(2-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(4-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(6-methyl-2-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(5-bromo-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(5-vinyl-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole;

(cis)-5-(1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrol-5-yl)nicotinonitrile;

(3aS,6aR)-5-(6-chloro-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole; and

(3aR,6aS)-5-(6-chloro-3-pyridinyl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrole.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030176/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2004
From: DART, MICHAEL J.; SEARLE, XENIA B.; TIETJE, KARIN R.; TOUPENCE, RICHARD B.
To: ABBOTT LABORATORIES
Reel/Frame 014500/0600 →
Continuity (2)
Provisional Application 6040373700 · Aug 14, 2002
Related Publication 20040152724A1 · Aug 5, 2004